cancer-therapy-and-biomarkers-2016_tracks-abstracts

29 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 60
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Formulation of liposomes for oral delivery of phyllanthin and hypophyllanthin
Thahera Parveen Dandu*1 and Madhukiran Parvathaneni2
1Oman Pharmaceutical Products (Gulf), Oman
2Harrisburg University of Science & Technology, USA
Formulation of liposomes in order to enhance the oral bioavailability of phyllanthin and hypophyllanthin with proven an-
ticancer activity. The bioactive lignans, Phyllanthin and hypophyllanthin are formulated in to conventional and PEGylated
liposomes using different ratios of DSPC, DSPE-MPEG2000 and cholesterol by film hydration technique. Evaluation of the
prepared liposomes was done by the determination of encapsulation efficiencies, particle size analysis, polydispersity index
(PDI), zeta potential, TEM analysis, IR studies, DSC studies and powder X-RD analysis. The drug retention in vitro and phar-
macokinetic properties in vivo are investigated. A new, simple and sensitive analytical method using HPLC with photodiode
array (PDA) detection was developed for the determination of phyllanthin and hypophyllanthin in solvent system and in
plasma.Conventional and pegylated liposomes are successfully formulated using film hydration technique with encapsulation
efficiencies of 86.47%±0.13% and 83.68±0.22% (phyllanthin), 84.83±0.19% and 81.87±0.54% (hypophyllanthin). The HPLC
method was successfully applied for quantification of lignans with recorded LOD and LOQ values of 56.15 ng/mL & 169.99
ng/mL (phyllanthin) and 56.04 ng/mL and 169.82 ng/mL (hypophyllanthin), respectively. From the in vivo pharmacokinetic
studies, it was observed that the oral bioavailability of lignans was enhanced as indicated by AUC values of 5265.30±275.52
ng.h/mL (phyllanthin), 15217.60±987.96 ng.h/mL (conventional liposomal phyllanthin), 30810.23±2587.96 ng.h/mL (pegylat-
ed liposomal phyllanthin) and 7354.42±578.2 ng.h/mL (hypophyllanthin), 29222.4±1951.8 ng.h/mL (conventional liposomal
hypophyllanthin), 58631.87±2515.46 ng.h/mL (pegylated liposomal hypophyllanthin). The developed liposomal formulations
of both the lignans, showed extended drug release over 24 h in in vitro drug release studies. Pharmacokinetic studies showed
the enhancement of oral bioavailability by several folds for liposomes. The enhanced oral bioavailability of lignan loaded lipo-
somes will be helpful for the production of desired pharmacological activity relatively at a lower dose when compared to their
respective free drugs.
Biography
ThaheraParveenDandu has completed her PhD at the age of 35 years from Andhra University. She is working as Deputy Manager, Formulation R&D atOman
Pharmaceutical Products, Gulf based pharmaceutical company. She has published more than 9 papers in reputed journals.
Madhukiran Parvathaneni has completed his PhD at the age of 26 years from NAIP/ICAR Project, Andhra University. He is working as Senior Regulatory Associate
with a global pharmaceutical CRO company. He has published more than 14 papers in reputed journals and serving as an editorial board member and reviewerfor
more than 10 PubMed, Springer and Elsevier Journals
Thahera Parveen Dandu et al., Oncol Cancer Case Rep 2016,2:3(Suppl)